ClinicalTrials.gg
CompletedNCT01261325BRITEUpdated Jul 22, 2022Results posted

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

A Phase 3 interventional study of Placebo and Brivaracetam in Epilepsy, sponsored by UCB Pharma. Completed at 207 sites in 28 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
768
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
2nd of 34
768 · median 94
Started
2010
the only one that year
Phase 3
21 of 34
1 open now
Registered
15th of 34
by date
Lead sponsor
13 of 34
UCB Pharma

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 2nd largest by enrollment, is the only one that started in 2010, is one of 21 in phase 3, and was the 15th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Brivaracetam
  • Partial Onset Seizures
  • Adjunctive treatment
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Well-characterized focal epilepsy/epileptic syndrome according to the 1989 International League Against Epilepsy (ILAE) classification
  • Presence of an EEG reading compatible with the clinical diagnosis of focal epilepsy within the last 5 years
  • Presence of a brain MRI/computed tomography (CT) scan performed within the last 2 years
  • Subjects having at least 8 Type I seizures [POS; focal seizures (according to the 1981 ILAE classification)] during the 8-week Baseline Period with at least 2 Type I seizures during each 4-week interval of the Baseline Period
  • Subjects having at least 2 partial onset seizures whether or not secondarily generalized per month during the 3 months preceding V1
  • Subjects being uncontrolled while treated by 1 or 2 permitted concomitant AED(s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED
  • Permitted concomitant AED(s) and VNS being stable and at optimal dosage for the subject from at least 1 month (3 months for phenobarbital, phenytoin, and primidone) before V1 and expected to be kept stable during the Baseline and Treatment Period. Benzodiazepine taken more than once a week (for any indication) will be considered as a concomitant AED

Exclusion criteria

Exclusion Criteria:

  • Subject previously randomized within this study or any other prior study with BRV as a dosing arm
  • Seizure type IA (1981 ILAE classification) nonmotor as only seizure type.
  • Subject is currently treated with LEV or has taken LEV within 90 days prior to V1
  • Subject has any medical or psychiatric condition, obvious cognitive impairment or mental retardation that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study
  • Subjects whose seizures could not be reliably counted on a regular basis due to their fast and repetitive occurrence (clusters or flurries)
  • Subject has history or presence of status epilepticus during the year preceding V1 or during Baseline
  • Subject has history or presence of known psychogenic nonepileptic seizures
  • Subject on felbamate with less than 18 months exposure before V1
  • Subject currently on vigabatrin. Subject with history of vigabatrin use but either no visual fields examination report available including standard static (Humphrey or Octopus) or kinetic perimetry (Goldman) or results of these examinations are abnormal
  • Subject taking any drug with possible central nervous system (CNS) effects except if stable from at least 1 month before V1 and expected to be kept stable during the Treatment Period
  • Subject has history of cerebrovascular accident, including , in the last 6 months
  • Subject is suffering from severe cardiovascular disease or peripheral vascular disease
  • Subject has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months
  • Subject has ongoing psychiatric disease other than mild controlled disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
768 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo tablets administered twice daily

    Drug: Placebo · Drug: Antiepileptic drugs with market authorization available per country

  • Experimental
    Brivaracetam 100 mg/ day

    Brivaracetam 50 mg/ day administered twice daily.

    Drug: Brivaracetam · Drug: Antiepileptic drugs with market authorization available per country

  • Experimental
    Brivaracetam 200 mg/ day

    Brivaracetam 100 mg/ day administered twice daily

    Drug: Brivaracetam · Drug: Antiepileptic drugs with market authorization available per country

Interventions

  • DrugPlacebo

    Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period

  • Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period

  • Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.

  • DrugAntiepileptic drugs with market authorization available per country
06

What researchers measure

Primary outcomes

  1. Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration

    Primary endpoint: United States of America (FDA)

    Time frame: 12 week Treatment Period

  2. 50% Responder Rate for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration

    Primary Endpoint: European Regulatory Authorities A responder is a participant who experienced a 50% or greater reduction in partial onset seizure (Type I) frequency over the Treatment Period standardized to a 28-day duration.

    Time frame: Baseline to 12 week Treatment Period

Secondary outcomes

  1. Percent Change in Partial Onset Seizure (Type I) Frequency From the Baseline to the Treatment Period

    Time frame: Baseline to 12 week Treatment Period

  2. Categorized Percent Reduction Form Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the Treatment Period

    Time frame: Baseline to 12 week Treatment Period

  3. Seizure Freedom Rate (All Seizure Types) During the 12-week Treatment Period

    Time frame: 12 week Treatment Period

  4. All Seizure Frequency (Type I + II + III) During the 12-week Treatment Period

    Time frame: 12 week Treatment Period

  5. Time to the First Type I Seizure During the Treatment Period

    Time frame: 12 week Treatment Period

  6. Time to the Fifth Type I Seizure During the Treatment Period

    Time frame: 12 week Treatment Period

  7. Time to the Tenth Type I Seizure During the Treatment Period

    Time frame: 12 week Treatment Period

07

Results

Posted Aug 15, 2016

Participant flow

Recruitment for the N01358 study began in December 2010. The study concluded in May 2014.

Participant flow — Overall Study
MilestonePlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
Started263254251
Completed246225225
Not completed172926
Withdrew: Lack of efficacy110
Withdrew: Withdrawal by subject224
Withdrew: Sae, non-fatal151
Withdrew: Ae, non-serious non-fatal91513
Withdrew: Sae, non-fatal+ae, non-serious non-fatal011
Withdrew: Non compliance200
Withdrew: Patient randomized by mistake010
Withdrew: Erroneously randomized100
Withdrew: Screen failure100
Withdrew: Randomized in error001
Withdrew: Protocol violation031
Withdrew: Lost to follow-up013
Withdrew: Ae, serious fatal002

Outcome measures

PrimaryPercent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration

Primary endpoint: United States of America (FDA)

Time frame:
12 week Treatment Period
Reported as:
Number · Percentage of reduction
Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration
Percentage of reductionBrivaracetam 100 mg/DayBrivaracetam 200 mg/DayPlacebo
Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration22.823.20
Statistical analysis
  • Brivaracetam 100 mg/Day · ANCOVA · p = <0.001 (Type I error rate of 0.05 based on a Hochberg multiple comparison procedure would be considered statistically significant" or similar, as accurate and appropriate.) · Percent reduction over pbo: 22.8 · 95% CI 13.3 to 31.2Effects of treatment, country, combination of LEV status and number of previous AEDs, and log-transformed baseline seizure frequency are in the model.
  • Brivaracetam 200 mg/Day · ANCOVA · p = <0.001 (Statistically significant with control of Type I error rate based on a Hochberg multiple comparison procedure.) · Percent reduction over pbo: 23.2 · 95% CI 13.8 to 31.6Effects of treatment, country, combination of LEV status and number of previous AEDs, and log-transformed baseline seizure frequency are in the model.
Primary50% Responder Rate for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration

Primary Endpoint: European Regulatory Authorities A responder is a participant who experienced a 50% or greater reduction in partial onset seizure (Type I) frequency over the Treatment Period standardized to a 28-day duration.

Time frame:
Baseline to 12 week Treatment Period
Reported as:
Number · Percentage of subjects
50% Responder Rate for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration
Percentage of subjectsPlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
Responders21.638.937.8
Non-Responders78.461.162.2
Statistical analysis
  • Placebo vs Brivaracetam 100 mg/Day · Regression, Logistic · p = <0.001 (Statistically significant with control of Type I error rate based on a Hochberg multiple comparison procedure.) · Odds ratio (brv versus pbo): 2.39 · 95% CI 1.6 to 3.6Effects of treatment, country, combination of LEV status and number of previous AEDs, and log-transformed baseline seizure frequency are in the model.
  • Placebo vs Brivaracetam 200 mg/Day · Regression, Logistic · p = <0.001 (Statistically significant with control of Type I error rate based on a Hochberg multiple comparison procedure.) · Odds ratio (brv versus pbo): 2.19 · 95% CI 1.5 to 3.3Effects of treatment, country, combination of LEV status and number of previous AEDs, and log-transformed baseline seizure frequency are in the model.
SecondaryPercent Change in Partial Onset Seizure (Type I) Frequency From the Baseline to the Treatment Period
Time frame:
Baseline to 12 week Treatment Period
Reported as:
Median · percentage of change
Percent Change in Partial Onset Seizure (Type I) Frequency From the Baseline to the Treatment Period
percentage of changePlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
Percent Change in Partial Onset Seizure (Type I) Frequency From the Baseline to the Treatment Period17.6 (-8.3 to 46.0)37.2 (0.1 to 69.4)35.6 (4.8 to 66.2)
Statistical analysis
  • Placebo vs Brivaracetam 100 mg/Day · Wilcoxon (Mann-Whitney) · p = <0.001 (Statistically significant at a nominal 0.050 significance level.) · Median difference vs placebo: 15.8 · 95% CI 7.6 to 24.2Hodges-Lehmann non-parametric effect estimates and corresponding two-sided 95% confidence intervals are provided above.
  • Placebo vs Brivaracetam 200 mg/Day · Wilcoxon (Mann-Whitney) · p = <0.001 (Statistically significant at a nominal 0.050 significance level.) · Median difference vs placebo: 18.1 · 95% CI 10.4 to 26.4Hodges-Lehmann non-parametric effect estimates and corresponding two-sided 95% confidence intervals are provided above.
SecondaryCategorized Percent Reduction Form Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the Treatment Period
Time frame:
Baseline to 12 week Treatment Period
Reported as:
Number · percentage of subjects
Categorized Percent Reduction Form Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the Treatment Period
percentage of subjectsPlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
<-25 %16.614.310.8
-25 % to <25 %40.528.629.3
25 % to <50 %21.218.322.1
50 % to <75 %13.919.018.1
75 % to <100 %6.913.913.7
100 %0.86.06.0
SecondarySeizure Freedom Rate (All Seizure Types) During the 12-week Treatment Period
Time frame:
12 week Treatment Period
Reported as:
Number · percentage of subjects
Seizure Freedom Rate (All Seizure Types) During the 12-week Treatment Period
percentage of subjectsPlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
Seizure free0.85.24.0
No seizures but discontinued0.41.21.2
Not seizure free98.893.794.8
SecondaryAll Seizure Frequency (Type I + II + III) During the 12-week Treatment Period
Time frame:
12 week Treatment Period
Reported as:
Median · number of seizures/ 28-day
All Seizure Frequency (Type I + II + III) During the 12-week Treatment Period
number of seizures/ 28-dayPlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
All Seizure Frequency (Type I + II + III) During the 12-week Treatment Period8.7 (4.3 to 23.6)6.3 (2.7 to 17.8)5.8 (2.3 to 14.2)
SecondaryTime to the First Type I Seizure During the Treatment Period
Time frame:
12 week Treatment Period
Reported as:
Median · days
Time to the First Type I Seizure During the Treatment Period
daysPlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
Time to the First Type I Seizure During the Treatment Period3 (2 to 3)5 (3 to 7)6 (4 to 7)
Statistical analysis
  • Placebo vs Brivaracetam 100 mg/Day · Semi-parametric hazards regression model · p = <0.001 (Statistically significant at a nominal 0.050 significance level.) · Hazard ratio (hr): 0.67 · 95% CI 0.56 to 0.82Hazard ratio is Brivaracetam versus Placebo.
  • Placebo vs Brivaracetam 200 mg/Day · Semi-parametric hazards regression model · p = <0.001 (Statistically significant at a nominal 0.050 significance level.) · Hazard ratio (hr): 0.65 · 95% CI 0.54 to 0.79Hazard ratio is Brivaracetam versus Placebo.
SecondaryTime to the Fifth Type I Seizure During the Treatment Period
Time frame:
12 week Treatment Period
Reported as:
Median · days
Time to the Fifth Type I Seizure During the Treatment Period
daysPlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
Time to the Fifth Type I Seizure During the Treatment Period16 (12 to 19)21 (17 to 25)23 (20 to 26)
Statistical analysis
  • Placebo vs Brivaracetam 100 mg/Day · Semi-parametric hazards regression model · p = <0.001 (Statistically significant at a nominal 0.050 significance level.) · Hazard ratio (hr): 0.65 · 95% CI 0.53 to 0.80Hazard ratio is Brivaracetam versus Placebo.
  • Placebo vs Brivaracetam 200 mg/Day · Semi-parametric hazards regression model · p = <0.001 (Statistically significant at a nominal 0.050 significance level.) · Hazard ratio (hr): 0.58 · 95% CI 0.47 to 0.71Hazard ratio is Brivaracetam versus Placebo.
SecondaryTime to the Tenth Type I Seizure During the Treatment Period
Time frame:
12 week Treatment Period
Reported as:
Median · days
Time to the Tenth Type I Seizure During the Treatment Period
daysPlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
Time to the Tenth Type I Seizure During the Treatment Period32 (24 to 36)37 (29 to 46)43 (36 to 49)
Statistical analysis
  • Placebo vs Brivaracetam 100 mg/Day · Semi-parametric hazards regression model · p = 0.009 (Statistically significant at a nominal 0.050 significance level.) · Hazard ratio (hr): 0.75 · 95% CI 0.60 to 0.93Effects of treatment, country, combination of LEV status and number of previous AEDs, and log-transformed baseline seizure frequency are in the model.
  • Placebo vs Brivaracetam 200 mg/Day · Semi-parametric hazards regression model · p = <0.001 (Statistically significant at a nominal 0.050 significance level.) · Hazard ratio (hr): 0.68 · 95% CI 0.55 to 0.85Effects of treatment, country, combination of LEV status and number of previous AEDs, and log-transformed baseline seizure frequency are in the model.

Adverse events

Collected over Treatment-emergent Adverse Events (TEAE) were collected during the study up to week 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—9/261 (3.4%)61/261 (23.4%)
Brivaracetam 100 mg/Day—8/253 (3.2%)96/253 (37.9%)
Brivaracetam 200 mg/Day—8/250 (3.2%)97/250 (38.8%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
FallInjury, poisoning and procedural complications0/2611/2532/250
PneumoniaInfections and infestations1/2310/2530/250
DeathGeneral disorders0/2610/2531/250
Sudden unexplained death in epilepsyGeneral disorders0/2610/2531/250
Localised infectionInfections and infestations0/2610/2531/250
Craniocerebral injuryInjury, poisoning and procedural complications0/2610/2531/250
Humerus fractureInjury, poisoning and procedural complications0/2610/2531/250
Grand mal convulsionNervous system disorders1/2610/2531/250
Seizure clusterNervous system disorders0/2610/2531/250
Adjustment disorderPsychiatric disorders0/2611/2531/250
Most frequent other events
Most frequent other events
EventPlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/Day
SomnolenceNervous system disorders20/26149/25342/250
DizzinessNervous system disorders13/26126/25336/250
FatigueGeneral disorders10/26119/25329/250
HeadacheNervous system disorders22/26117/25320/250
Urinary tract infectionInfections and infestations8/26113/2532/250

Baseline characteristics

Baseline Characteristics consist of the Randomized Set (RS). The RS includes all subjects that were randomized.

Age, Continuous
Age, Continuous(years)PlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/DayTotal Title
Mean39.8 ± 12.839.0 ± 13.439.7 ± 12.839.5 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/DayTotal Title
Female128152117397
Male135102134371
Weight
Weight(kilograms)PlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/DayTotal Title
Median76.1 ± 19.974.1 ± 16.875.5 ± 19.075.2 ± 18.6
Height
Height(centimeters)PlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/DayTotal Title
Mean168.4 ± 10.0166.6 ± 9.8168.7 ± 9.9167.9 ± 9.9
BMI
BMI(kg/m^2)PlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/DayTotal Title
Mean26.6 ± 5.726.7 ± 5.626.4 ± 6.026.6 ± 5.8
Racial Group
Racial Group(participants)PlaceboBrivaracetam 100 mg/DayBrivaracetam 200 mg/DayTotal Title
American Indian or Alaska Native1081129
Asian32322993
Black or African American118726
White190183183556
Other17211856
Missing3238
08

Study locations

207 sites
  • 001
    Phoenix, Arizona, United States
  • 013
    Phoenix, Arizona, United States
  • 006
    Tucson, Arizona, United States
  • 775
    Little Rock, Arkansas, United States
  • 045
    Sacramento, California, United States
  • 025
    San Francisco, California, United States
  • 060
    Aurora, Colorado, United States
  • 085
    Colorado Springs, Colorado, United States
  • 071
    Miami, Florida, United States
  • 110
    Miami, Florida, United States
  • 073
    Naples, Florida, United States
  • 090
    Ocala, Florida, United States
  • 027
    Orlando, Florida, United States
  • 064
    Port Charlotte, Florida, United States
  • 044
    Sarasota, Florida, United States
  • 023
    Atlanta, Georgia, United States
  • 063
    Atlanta, Georgia, United States
  • 062
    Columbus, Georgia, United States
  • 048
    Rome, Georgia, United States
  • 039
    Boise, Idaho, United States
  • 005
    Peoria, Illinois, United States
  • 017
    Winfield, Illinois, United States
  • 020
    Ames, Iowa, United States
  • 069
    Iowa City, Iowa, United States
  • 780
    Lexington, Kentucky, United States
  • 092
    Hammond, Louisiana, United States
  • 008
    Bethesda, Maryland, United States
  • 068
    Waldorf, Maryland, United States
  • 055
    East Lansing, Michigan, United States
  • 009
    Golden Valley, Minnesota, United States
  • 051
    Missoula, Montana, United States
  • 032
    Lebanon, New Hampshire, United States
  • 042
    Hamilton, New Jersey, United States
  • 058
    Voorhees, New Jersey, United States
  • 095
    Kingston, New York, United States
  • 022
    New York, New York, United States
  • 099
    New York, New York, United States
  • 098
    Poughkeepsie, New York, United States
  • 010
    Asheville, North Carolina, United States
  • 003
    Durham, North Carolina, United States
  • 096
    Canton, Ohio, United States
  • 034
    Cleveland, Ohio, United States
  • 070
    Columbus, Ohio, United States
  • 002
    Toledo, Ohio, United States
  • 043
    Oklahoma City, Oklahoma, United States
  • 091
    Oklahoma City, Oklahoma, United States
  • 054
    Tulsa, Oklahoma, United States
  • 015
    Philadelphia, Pennsylvania, United States
  • 028
    Charleston, South Carolina, United States
  • 021
    Port Royal, South Carolina, United States
  • 050
    Arlington, Texas, United States
  • 061
    Austin, Texas, United States
  • 011
    Dallas, Texas, United States
  • 035
    Dallas, Texas, United States
  • 049
    Houston, Texas, United States
  • 036
    Charlottesville, Virginia, United States
  • 033
    Seattle, Washington, United States
  • 056
    Spokane, Washington, United States
  • 052
    Madison, Wisconsin, United States
  • 057
    Milwaukee, Wisconsin, United States
  • 089
    Casper, Wyoming, United States
  • 202
    Innsbruck, Austria
  • 201
    Linz, Austria
  • 200
    Wien, Austria
  • 203
    Wien, Austria
  • 226
    Hechteleksel, Belgium
  • 227
    Leuven, Belgium
  • 228
    Liege, Belgium
  • 104
    Belo Horizonte, Brazil
  • 100
    Florianopolis, Brazil
  • 103
    Riberao Preto, Brazil
  • 101
    Sao Paulo, Brazil
  • 294
    Blagoevrad, Bulgaria
  • 286
    Sofiya, Bulgaria
  • 287
    Sofiya, Bulgaria
  • 075
    Calgary, Alberta, Canada
  • 078
    London, Ontario, Canada
  • 076
    Toronto, Ontario, Canada
  • 077
    Greenfield Park, Quebec, Canada
  • 079
    Montreal, Quebec, Canada
  • 080
    Saskatoon, Saskatchewan, Canada
  • 916
    Kromeriz, Czechia
  • 913
    Ostrava Poruba, Czechia
  • 251
    Ostrava, Czechia
  • 256
    Ostrava, Czechia
  • 252
    Praha 1, Czechia
  • 253
    Praha 4, Czechia
  • 250
    Zlin, Czechia
  • 650
    Tallinn, Estonia
  • 652
    Tallinn, Estonia
  • 653
    Tallinn, Estonia
  • 651
    Tartu, Estonia
  • 275
    Kuopio, Finland
  • 278
    Oulu, Finland
  • 276
    Tampere, Finland
  • 277
    Turku, Finland
  • 301
    Bethune, France
  • 308
    Marseille, France
  • 305
    Montpellier, France
  • 329
    Berlin, Germany

Showing the first 100 of 207 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, Borghs S, Kwan P. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016 Jul;57(7):1139-51. doi: 10.1111/epi.13416. Epub 2016 Jun 6. PubMed 27265725 ↗
  • Ben-Menachem E, Mameniskiene R, Quarato PP, Klein P, Gamage J, Schiemann J, Johnson ME, Whitesides J, McDonough B, Eckhardt K. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016 Jul 19;87(3):314-23. doi: 10.1212/WNL.0000000000002864. Epub 2016 Jun 22. PubMed 27335114 ↗
  • Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015 Dec;56(12):1890-8. doi: 10.1111/epi.13212. Epub 2015 Oct 16. PubMed 26471380 ↗
  • Brodie MJ, Whitesides J, Schiemann J, D'Souza J, Johnson ME. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Res. 2016 Nov;127:114-118. doi: 10.1016/j.eplepsyres.2016.08.018. Epub 2016 Aug 18. PubMed 27589414 ↗
  • Moseley BD, Sperling MR, Asadi-Pooya AA, Diaz A, Elmouft S, Schiemann J, Whitesides J. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies. Epilepsy Res. 2016 Nov;127:179-185. doi: 10.1016/j.eplepsyres.2016.09.003. Epub 2016 Sep 3. PubMed 27608437 ↗
  • Brandt C, Borghs S, Elmoufti S, Mueller K, Townsend R, de la Loge C. Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis. Epilepsy Behav. 2017 Apr;69:80-85. doi: 10.1016/j.yebeh.2016.11.031. Epub 2017 Feb 23. PubMed 28236727 ↗
  • Klein P, Johnson ME, Schiemann J, Whitesides J. Time to onset of sustained >/=50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment. Epilepsia. 2017 Feb;58(2):e21-e25. doi: 10.1111/epi.13631. Epub 2016 Dec 18. PubMed 27988967 ↗
  • Asadi-Pooya AA, Sperling MR, Chung S, Klein P, Diaz A, Elmoufti S, Schiemann J, Whitesides J. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study. Epilepsy Res. 2017 Mar;131:70-75. doi: 10.1016/j.eplepsyres.2017.02.007. Epub 2017 Feb 27. Erratum In: Epilepsy Res. 2017 Nov;137:165-166. doi: 10.1016/j.eplepsyres.2017.04.019. PubMed 28279891 ↗
  • Benbadis S, Klein P, Schiemann J, Diaz A, Elmoufti S, Whitesides J. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis. Epilepsy Behav. 2018 Mar;80:129-134. doi: 10.1016/j.yebeh.2017.12.024. Epub 2018 Feb 3. PubMed 29414542 ↗
  • Brodie MJ, Fakhoury T, McDonough B, Colson AO, Stockis A, Elmoufti S, Whitesides J. Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program. Epilepsy Res. 2018 Sep;145:55-62. doi: 10.1016/j.eplepsyres.2018.06.002. Epub 2018 Jun 4. PubMed 29908435 ↗
  • Klein P, Laloyaux C, Elmoufti S, Gasalla T, Martin MS. Time course of 75%-100% efficacy response of adjunctive brivaracetam. Acta Neurol Scand. 2020 Aug;142(2):175-180. doi: 10.1111/ane.13287. Epub 2020 Jun 9. PubMed 32432339 ↗
  • Moseley BD, Dimova S, Elmoufti S, Laloyaux C, Asadi-Pooya AA. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis. Epilepsy Res. 2021 Oct;176:106694. doi: 10.1016/j.eplepsyres.2021.106694. Epub 2021 Jun 24. PubMed 34218211 ↗
  • Ryvlin P, Dimova S, Elmoufti S, Floricel F, Laloyaux C, Nondonfaz X, Biton V. Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials. Epilepsia. 2022 Aug;63(8):2024-2036. doi: 10.1111/epi.17304. Epub 2022 Jun 10. PubMed 35582748 ↗
  • Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2022 Mar 14;3(3):CD011501. doi: 10.1002/14651858.CD011501.pub3. PubMed 35285519 ↗
  • Lee SK, Heo K, Kim SE, Lee SA, Elmoufti S, Laloyaux C, Hur B. Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam for Uncontrolled Focal Seizures: Post Hoc Analysis. Adv Ther. 2021 Jul;38(7):4082-4099. doi: 10.1007/s12325-021-01816-5. Epub 2021 Jun 21. PubMed 34155568 ↗
  • Toledo M, Brandt C, Quarato PP, Schulz AL, Cleveland JM, Wagener G, Klein P. Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial. Epilepsy Behav. 2021 May;118:107897. doi: 10.1016/j.yebeh.2021.107897. Epub 2021 Mar 27. PubMed 33780735 ↗
  • Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6. PubMed 26899665 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 2 years 3 months after primary completion. A results delay was requested in Apr 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2010
First posted
Dec 16, 2010
Start
Dec 2010
Primary completionActual
May 2014
CompletionActual
May 2014
Results delay requested
Apr 27, 2015
Results first posted
Aug 15, 2016
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01261325
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Dec 16, 2010
Start date
Dec 2010
Primary completion
May 2014
Completion
May 2014
Results posted
Aug 15, 2016
Last update
Jul 22, 2022

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion